Dr Markus Osypka, President and CEO of Osypka Medical said "We believe in hemodynamically optimized pacing therapy. Ceryx’s Cysoni technology has the potential to become another quantum leap in pacing therapy very much like A-V synchronous pacing is today, but without placing the additional burden on the operator".

Over the next few months, the teams at Ceryx and Osypka will work together to refine the device for clinical trials, which will take place in the UK and New Zealand. This will involve heart failure patients who have undergone a coronary artery bypass being fitted with this external device. These patients are usually paced for just a few hours after surgery, but the Ceryx team plans to extend this in order to build a full picture of Cysoni’s capabilities.

"All of our data so far points to Cysoni being capable of doing things no other pacing device has been able to do," said Dr Plant. It’s the result of ground-breaking research at the Universities of Bath and Bristol. The technology has also undergone five years of rigorous laboratory testing and pre-clinical evaluations as part of our collaboration with the University of Auckland in New Zealand. This next step, in partnership with Osypka, takes us within touching distance of making Cysoni available to the global healthcare community."